Gastrointestinal Cancer
Cancer Type
Tumor Tissue (FFPE)
Specimen Requirements
6 Working Days
Turnaround Time ¹
ACTDrug® GI is an NGS‑based test that detects 20 clinically actionable genes in gastrointestinal cancer-tumor tissue. These genes align with FDA‑approved and NCCN-guideline-recommended targeted therapies, supporting timely and informed treatment decisions.
Actionable Insights for Timely Treatment Options
20
Cancer Genes
11
Fusion Genes
6
Days Turnaround Time
Hallmarks of ACTDrug® GI
20 genes
Assesses clinically relevant gene alterations for gastrointestinal cancer, aligned with FDA-approved and NCCN guideline-recommended targeted therapies, supporting informed first-line treatment decisions
Whole Coding-Region Design
Comprehensive variant detection and identification of clinically actionable alterations.
Resistance Mutation Insight
Provides genomic insights into variants associated with treatment resistance.
RNA-based NGS Fusion Detection
Enables assessment of known and novel gene fusion events, supporting the identification of patients who may benefit from targeted therapy.
6 Working Days
Rapid turnaround time.
Summary
Actionable Insights of Biomarkers for Your Cancer Patient
Provides genomic profiling for clinically actionable genes. Specifically for gastrointestinal cancer.
Timely Treatment Options Through Cancer Genomic Profiling
ACTDrug® GI is a next-generation sequencing (NGS)-based assay that provides 20 actionable genes and 11 fusion genes insights, tailored for gastrointestinal cancer. Sequencing is performed from cancer specimens in our CAP-accredited laboratory. This assay is designed for gastrointestinal cancer patients, providing tailored genomic profiling and targeted drug recommendations.
Explore Various Genetic Alterations for More Therapeutic Implications
ACTDrug® GI performs various genetic variation analyses. In addition to single-nucleotide variation (SNV) and small insertions/deletions (InDels), the assay detects copy number variations (CNVs), gene fusions, and microsatellite instability (MSI), providing clinically relevant alterations.
For Gastrointestinal Cancer Management
Selects the most suitable treatment for newly diagnosed advanced and/ or metastatic patients based on actionable genetic mutations.
Easy-to-Interpret Medical Report
Actionable summary of the detected variant and associated therapies. Variant reporting and classification are based on levels of evidence, prioritizing treatment-related evidence supported by international publications and guidelines.
Technical Specifications
Next Generation Sequencing (NGS)
20 actionable genes
Specimen Requirements2
FFPE Tumor Tissue
5-20 unstained sections (5 μm/slide,surface area ≥ 125 mm2)
1 H&E-stained slide (5 μm)
Sequencing Mean Depth
≥ 600 x
Sensitivity3
SNV and Indels: 100%, CNAs: 95%, LGR(BRCA1/2): 100%, Fusion 100%, MSI: 100%
Specificity 3
SNV and Indels: 100%, CNAs: 100%, LGR (BRCA1/2): 94%, Fusion 100%, MSI: 94%
Documentation
Disclaimers / Footnotes
- Turnaround time starts from the date of receipt of qualified samples at our CAP-accredited laboratory.\
- Please refer to our specimen instructions.
- Analytical performance was established under defined validation conditions
